LENZ Therapeutics, Inc. — Director's Dealing 2023

Aug 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Graphite Bio, Inc. (GRPH)
CIK: 0001815776
Period of Report: 2023-07-28

Reporting Person: Drapkin Kimberlee C (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-07-28	Stock Option (right to buy)	$2.52	A	40000	Acquired	2033-07-27	Common Stock (40000)	Direct

Footnotes

F1: 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 28, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.